Document is current
Any future updates will be listed below
-
Authors
Weller, Michael http://orcid.org/0000-0002-1748-174X
Wen, Patrick Y.
Chang, Susan M.
Dirven, Linda
Lim, Michael
Monje, Michelle http://orcid.org/0000-0002-3547-237X
Reifenberger, Guido
- License Information
-
More Information
Article History
Accepted: 3 April 2024
First Online: 9 May 2024
Competing interests
: M.W. has received research grants from Novartis, Quercis and Versameb, and honoraria for lectures or advisory board participation or consulting from Bayer, Curevac, Medac, Merck (EMD), Novartis, Novocure, Orbus, Philogen and Servier. P.Y.W. has received research grants from Amgen, Angiochem, AstraZeneca, Exelixis, Genentech/Roche, GlaxoSmithKline, Merck, Novartis, Sanofi–Aventis and Vascular Biogenics and honoraria for lectures or advisory board participation from AbbVie, Celldex, Foundation Medicine, Genentech/Roche, Merck, Novartis, Vascular Biogenics, Midatech and Monteris. M.L. has received research support from Arbor, Accuray and Biohaven and honoraria from VBI, InCephalo Therapeutics, Merck, Pyramid Bio, Insightec, Biohaven, Sanianoia, Hemispherian, Novocure, Noxxon, InCando, Hoth, CraniUs, MediFlix and GCAR. He is a shareholder for Egret Therapeutics. M.M. holds equity in MapLight Therapeutics and is on the SAB for TippingPoint Biosciences. G.R., S.M.C. and L.D. declare no competing interests.
